Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS|May 24, 2007
A robotic C-arm fluoroscopeN Binder, L Matthäus, R Burgkart, et al.
Pediatric Transplantation|February 16, 2007
Polymyositis--an unusual presentation of cGvHD in childrenR Klein, P Franck, S Ehl, et al.
American Journal of Perinatology|May 1, 1994
Measurement of transcutaneous carbon dioxide in low birthweight infants during the first two weeks of lifeN Binder, H Atherton, T Thorkelsson, et al.
European Journal of Immunology|March 31, 2000
Donor cell persistence and activation-induced unresponsiveness of peripheral CD8+ T cellsS Ehl, W Barchet, S Oehen, et al.
Immunological Reviews|July 10, 1999
General and specific immunosuppression caused by antiviral T-cell responsesR M Zinkernagel, O Planz, S Ehl, et al.
The Journal of Experimental Medicine|March 28, 1998
Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathologyS Ehl, J Hombach, P Aichele, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 1997
A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriersO Planz, S Ehl, E Furrer, et al.
Clinical and Experimental Immunology|July 19, 2008
Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiencyJ Litzman, T Freiberger, B Grimbacher, et al.
Nature Medicine|September 12, 1998
Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejectionS Ehl, P Aichele, H Ramseier, et al.
Dermatology (Basel, Switzerland)|September 11, 2001
Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon)I Worret, W Arp, H P Zahradnik, et al.
Pageof 6